These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 29143276

  • 1. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [Abstract] [Full Text] [Related]

  • 2. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K.
    Neurology; 2007 May 22; 68(21):1831-6. PubMed ID: 17515545
    [Abstract] [Full Text] [Related]

  • 3. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 22; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 4. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M, Faedi M, Bello L, Migliore E, Marchese G, Bertero L, Cassoni P, Soffietti R.
    J Neurooncol; 2019 Oct 01; 145(1):115-123. PubMed ID: 31556015
    [Abstract] [Full Text] [Related]

  • 6. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S, Chatterjee A, Gupta T, Panda P, Moiyadi A, Epari S, Patil V, Krishnatry R, Goda JS, Jalali R.
    World Neurosurg; 2021 Oct 01; 154():e176-e184. PubMed ID: 34245877
    [Abstract] [Full Text] [Related]

  • 7. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X.
    Neurosurg Rev; 2021 Jun 01; 44(3):1447-1455. PubMed ID: 32529528
    [Abstract] [Full Text] [Related]

  • 8. Dynamic history of low-grade gliomas before and after temozolomide treatment.
    Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY.
    Ann Neurol; 2007 May 01; 61(5):484-90. PubMed ID: 17469128
    [Abstract] [Full Text] [Related]

  • 9. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
    Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T.
    Cancer; 2006 Apr 15; 106(8):1759-65. PubMed ID: 16541434
    [Abstract] [Full Text] [Related]

  • 10. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA, van den Bent MJ.
    Eur J Cancer; 2006 Oct 15; 42(15):2499-503. PubMed ID: 16914310
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
    van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.
    Lancet Oncol; 2018 Sep 15; 19(9):1170-1179. PubMed ID: 30115593
    [Abstract] [Full Text] [Related]

  • 12. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M, GICNO.
    J Clin Oncol; 2006 Oct 10; 24(29):4746-53. PubMed ID: 16954518
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.
    J Neurooncol; 2015 Mar 10; 122(1):111-9. PubMed ID: 25534576
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.
    J Neurooncol; 2016 Sep 10; 129(3):505-514. PubMed ID: 27401154
    [Abstract] [Full Text] [Related]

  • 17. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
    Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.
    Acta Neuropathol; 2018 Apr 10; 135(4):601-615. PubMed ID: 29368212
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F, Pontoizeau C, Tchara L, Di Stefano AL, Kamoun A, Deelchand DK, Valabrègue R, Lehéricy S, Sanson M, Ottolenghi C, Marjańska M.
    Neuro Oncol; 2019 Jun 10; 21(6):765-774. PubMed ID: 30726924
    [Abstract] [Full Text] [Related]

  • 20. Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence.
    Akkus Z, Ali I, Sedlář J, Agrawal JP, Parney IF, Giannini C, Erickson BJ.
    J Digit Imaging; 2017 Aug 10; 30(4):469-476. PubMed ID: 28600641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.